Skip to main content
OpenTrials
Completed

NCT Number: NCT06566677

Point of Care Rapid STI Test Optimization and Validation Extension

The purpose of this sub-study (PROVE) is to support and facilitate the validation of commercially available point of care (POC) sexually transmitted infection (STI) diagnostic test kits/devices for potential on-site laboratory use as well as bedside use in parallel to gold standard established testing methodologies. A further extension of bedside testing would include self-testing.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Screening and Enrolment procedures for the ARISE study (HREC Ref No. 210614) involves adolescent girls and young women (AGYW) being screened for Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) as determined through testing of clinician-collected genital swabs followed by GeneXpert, OSOM rapid TV testing or through wet mount visualisation of the micro-organisms of interest. This will generate a pool of AGYW with known STI diagnoses who, if positive, will be treated on-site on the day of STI detection. It will also create an ideal opportunity to leverage access to samples from willing participants (prior to STI treatment if STI positive) for validation of a range of alternate STI test kits. Samples provided will enable same-day parallel testing on additional platforms for validation of the sensitivity and specificity of these alternate tests against the known validated platformsThis initiative will expand the menu of cost effective and user friendly STI test kits that may ultimately be used in other research studies, in public clinic settings and as self-tests performed discretely in the convenience and privacy of one's home.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must meet the following criteria to be eligible for inclusion in the study:

  • Cisgender adolescent girls and young women (18-25 years of age, inclusive), screened for or enrolled in the ARISE study.
  • Willing to provide written informed consent to participate in this sub-study.
  • Willing to provide additional samples including vaginal and endocervical swabs, urine and those collected through the use of tampons and disposable menstrual cups.

Exclusion criteria

  • Cisgender male or transgender woman or transgender man
  • Age <18 years
  • Unable or unwilling to provide written informed consent
  • Have any condition that in the opinion of the investigators will interfere with successful completion of sub-study procedures

Treatment and study plan

Primary outcomes

  1. GeneXpert

    Time frame: 1 year

    A PCR instrument was used to assess the presence of chlamydia trichomatis and gonorrhea from samples taken using endocervical swabs.

Secondary outcomes

  1. Osom rapid testing kit

    Time frame: 1 year

    A rapid point-of-care test for the diagnosis of Trichomonas vaginalis in women using dacron swabs.

Other outcomes

  1. JD Biotech Trichomonas vaginalis antigen rapid test kit

    Time frame: 1 year

    Trichomonas vaginalis antigen rapid test kit

  2. JD Biotech C. Trachomatis/ N. Gonorrhoeae Ag combo rapid test

    Time frame: 1 year

    Urine or vaginal cavity swab or vaginal glans sample to diagnose chlamydia trichomati and gonorroea

  3. Cromatest Chlamydia one step rapid kit

    Time frame: 1 year

    Female cervical swab and male urethral swab specimens to diagnose chlamydia

  4. NADAL Chlamydia Test

    Time frame: 1 year

    Female or male urethral swab/male Urine used to diagnose chlamydia

  5. ACRO Biotech Gonorrhoea

    Time frame: 1 year

    Female cervical swab/ male urethral swab to diagnose gonorrhoea

  6. Rapid Labs Gonorrhea

    Time frame: 1 year

    Sterile Female cervical swab/ male urethral swab to diagnose gonorrhea

Sponsors and collaborators

Lead sponsor

Wits RHI Research Centre Clinical Research Site

Other

Collaborators

  • University of Washington

Registry information

Official study title

Validation of Selected Point of Care Rapid STI Diagnostic Tests for Laboratory Based and Self- Test Use - A Sub-Study of Acceptability Research on Integrated Point of Care Sexually Transmitted Infection (STI) Testing and Expanded Partner Therapy (EPT) (ARISE)

Acronym: PROVE

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 22, 2024
Registry last updated
Aug 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.